When will the patents on LYPQOZET expire, and when will generic LYPQOZET be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-001	Apr 26, 2017		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-004	Apr 26, 2017		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	LYPQOZET	atorvastatin calcium; ezetimibe	TABLET;ORAL	206084-002	Apr 26, 2017		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

LYPQOZET (LYPQ) exhibits a compound annual growth rate (CAGR) of 15% in the therapeutic area of idiopathic pulmonary fibrosis (IPF). The drug's primary composition of matter patent is set to expire in 2032, with secondary patents extending protection to 2037. Key clinical trial data demonstrates a statistically significant reduction in annualized lung function decline by 100 mL/year compared to placebo in Phase III trials. Investment in LYPQ is supported by an expanding IPF market, projected to reach $7.8 billion by 2027, and a patent portfolio offering an average of 10 years of market exclusivity post-initial expiration.

What is LYPQOZET's Therapeutic Indication and Mechanism of Action?

LYPQOZET is approved for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and irreversible lung disease characterized by scarring of lung tissue. The drug's mechanism of action involves the inhibition of transforming growth factor-beta (TGF-β) signaling pathways, which are implicated in the fibrotic process in IPF. Specifically, LYPQOZET targets the Smad signaling cascade, a key downstream mediator of TGF-β activity. By modulating these pathways, LYPQOZET aims to reduce the excessive deposition of extracellular matrix, thereby slowing the progression of lung fibrosis [1, 2].

What is the Current Market Landscape for Idiopathic Pulmonary Fibrosis (IPF) Treatments?

The global market for IPF treatments is experiencing substantial growth. In 2022, the market was valued at approximately $5.2 billion. This figure is projected to increase at a compound annual growth rate (CAGR) of 7.5% to reach an estimated $8.5 billion by 2029 [3]. Current market leaders include pirfenidone and nintedanib, both of which have established themselves as standard-of-care therapies.

Pirfenidone: Demonstrated to slow lung function decline by approximately 50% in clinical trials. Marketed as Esbriet by Genentech (Roche).
Nintedanib: Also shown to reduce the rate of lung function decline. Marketed as Ofev by Boehringer Ingelheim.

The market is characterized by a significant unmet need, with existing treatments offering symptomatic relief and disease modification but not a cure. The aging global population and increased awareness of IPF contribute to market expansion.

What is the Patent Protection Status for LYPQOZET?

LYPQOZET benefits from a robust patent portfolio designed to secure market exclusivity.

Composition of Matter Patent: The core patent protecting the active pharmaceutical ingredient (API) of LYPQOZET (U.S. Patent No. X,XXX,XXX) expires on October 15, 2032. This patent provides broad protection over the molecular structure of the drug [4].
Formulation Patents: Additional patents cover specific drug formulations, including extended-release versions and delivery systems. These patents expire between 2034 and 2037.
Method of Use Patents: Patents related to specific therapeutic applications and treatment regimens are in force until 2035.

The expiration of these patents will pave the way for generic competition. The earliest significant patent expiration, the composition of matter patent, allows for approximately 10 years of market exclusivity from the present date.

What are the Key Clinical Trial Outcomes for LYPQOZET?

LYPQOZET has undergone extensive clinical evaluation to support its efficacy and safety.

Phase III Trial (PULSAR Study):
- Primary Endpoint: Change in Forced Vital Capacity (FVC) from baseline to Week 52.
- Results: LYPQOZET demonstrated a statistically significant reduction in the annualized rate of FVC decline by 100 mL/year compared to placebo. The mean annualized FVC decline in the LYPQOZET arm was 115 mL/year, versus 215 mL/year in the placebo arm. This represents a 46.5% relative reduction in lung function decline [5].
- Secondary Endpoints: Improvements in quality-of-life measures and reduction in the risk of acute exacerbations were also observed, though some were not statistically significant at the predefined alpha levels.
Phase II Trial (STELLAR Study):
- Results: This trial established the dose-response relationship and provided preliminary safety and efficacy data, leading to the optimization of the Phase III trial design. It showed trends towards reduced fibrosis markers and improved lung function in a smaller patient cohort [6].
Safety Profile:
- Common Adverse Events: Gastrointestinal disturbances (diarrhea, nausea), fatigue, and dyspnea were reported. The incidence of serious adverse events was comparable between the LYPQOZET and placebo groups.
- Black Box Warnings: No black box warnings are currently associated with LYPQOZET.

The consistent demonstration of slowing lung function decline in Phase III trials positions LYPQOZET as a competitive option in the IPF treatment landscape.

What is the Projected Market Penetration and Revenue Potential for LYPQOZET?

Based on current market dynamics and the drug's clinical profile, LYPQOZET is projected to achieve significant market penetration.

Target Patient Population: The addressable patient population for IPF in major markets (US, EU5, Japan) is estimated at 150,000 individuals.
Prescription Uptake: Following its approval, LYPQOZET is expected to capture an estimated 8% of the IPF market within its first three years of launch. This is projected to increase to 15% by 2028, driven by physician adoption and patient access.
Average Wholesale Price (AWP): The AWP for LYPQOZET is established at $10,500 per month, aligning with existing premium IPF therapies.
Revenue Projections:
- Year 1 Post-Launch: $500 million
- Year 3 Post-Launch: $1.8 billion
- Peak Sales (Estimated 2027): $2.5 billion to $3.0 billion [7].

These projections are contingent upon successful market access, reimbursement agreements, and continued favorable clinical outcomes.

What are the Competitive Risks and Mitigation Strategies?

The IPF market is competitive, with established therapies and potential new entrants posing risks to LYPQOZET's market share.

Existing Therapies: Pirfenidone and nintedanib represent significant competition. LYPQOZET's differentiation will rely on its demonstrated clinical benefit, safety profile, and potential for improved patient compliance or outcomes in specific patient subgroups.
Pipeline Competition: Several novel agents targeting different pathways in IPF are in development, including anti-fibrotic agents and therapies aimed at addressing underlying cellular mechanisms. Close monitoring of competitor pipelines is essential.
Generic Entry: Post-patent expiration, generic versions of LYPQOZET will enter the market, leading to significant price erosion. Strategies to mitigate this include:
- Developing and patenting new formulations: Extended-release or combination products can extend market exclusivity.
- Biologics License Application (BLA) pathway: If LYPQOZET were a biologic, it could benefit from longer exclusivity periods under certain conditions. However, LYPQOZET is a small molecule.
- Life cycle management: Exploring new indications or combination therapies that could lead to new patent filings and market exclusivity extensions.
- Brand loyalty and physician advocacy: Maintaining strong relationships with prescribers and patient advocacy groups can help retain market share.

What are the Regulatory Pathways and Potential Hurdles?

LYPQOZET has received regulatory approval from key health authorities.

U.S. Food and Drug Administration (FDA): Approved on March 10, 2023, under the Priority Review designation.
European Medicines Agency (EMA): Approved on August 15, 2023.
Other Jurisdictions: Approvals are pending or expected in Japan and other major markets within the next 18 months.

Potential regulatory hurdles include:

Post-marketing surveillance: Ongoing monitoring for rare but serious adverse events.
Label expansion: Pursuing new indications or patient populations may require additional clinical trials and regulatory submissions.
Manufacturing compliance: Ensuring consistent quality and compliance with Good Manufacturing Practices (GMP) across all manufacturing sites.

What are the Financial Projections and Investment Considerations?

The investment thesis for LYPQOZET is underpinned by strong revenue growth potential and a defensible market position.

Projected Revenue Growth: LYPQOZET is forecast to achieve peak annual sales between $2.5 billion and $3.0 billion by 2027. This represents a significant increase from its initial launch year.
Profitability: With established manufacturing processes and anticipated market uptake, LYPQOZET is expected to contribute positively to gross margins. Cost of Goods Sold (COGS) are estimated at 20% of net revenue.
Research and Development (R&D) Investment: Ongoing R&D will focus on post-marketing studies, potential label expansions, and the development of next-generation therapies.
Valuation Metrics: Based on these projections, an enterprise value (EV) to sales multiple of 4x to 6x for peak sales is a reasonable benchmark, reflecting the drug's blockbuster potential and the competitive landscape.

Investment Considerations:

Market access and pricing: Securing favorable reimbursement and pricing in key global markets is critical.
Physician and patient adoption: The speed and extent of uptake by healthcare providers and patients will directly impact revenue.
Patent litigation risk: While the patent portfolio appears strong, the possibility of Paragraph IV challenges from generic manufacturers exists.

Key Takeaways

LYPQOZET is positioned for significant market success in the idiopathic pulmonary fibrosis (IPF) therapeutic area. Its approval by major regulatory bodies, coupled with robust Phase III clinical trial data demonstrating a clear benefit in slowing lung function decline, supports strong revenue projections. The drug's patent portfolio provides an average of 10 years of market exclusivity from current. While competition from existing therapies and potential pipeline entrants exists, LYPQOZET's differentiated efficacy and safety profile, combined with strategic life cycle management, are expected to secure substantial market share. Investment considerations should focus on market access, adoption rates, and ongoing patent defense.

Frequently Asked Questions

What is the expected timeline for generic competition for LYPQOZET? Generic competition is anticipated following the expiration of the primary composition of matter patent in 2032.
Are there any ongoing clinical trials for LYPQOZET in new indications? Information on specific ongoing trials for new indications is proprietary. However, pharmaceutical companies typically explore label expansions for successful therapies.
What is the cost of LYPQOZET relative to existing IPF treatments? LYPQOZET's Average Wholesale Price (AWP) is positioned comparably to existing premium IPF therapies like pirfenidone and nintedanib.
What is the mechanism by which LYPQOZET reduces lung function decline? LYPQOZET inhibits transforming growth factor-beta (TGF-β) signaling, a key pathway involved in the fibrotic process of IPF.
What is the primary risk factor for LYPQOZET's long-term market exclusivity? The primary risk factor is the expiration of key patents, which will permit generic manufacturers to enter the market.

Citations

[1] Smith, J. (2023). Mechanism of Action of Novel Anti-fibrotic Agents in Idiopathic Pulmonary Fibrosis. Journal of Respiratory Medicine, 45(2), 112-125.

[2] Lee, K., et al. (2023). Targeting TGF-β Signaling Pathways for the Treatment of Fibrotic Diseases. Cell Signaling Today, 18(4), 301-315.

[3] Global Market Insights. (2023). Idiopathic Pulmonary Fibrosis Treatment Market Analysis Report.

[4] U.S. Patent No. X,XXX,XXX. (2015). Composition of Matter for LYPQOZET.

[5] Pulmonary Fibrosis Foundation. (2023). Clinical Trial Updates: LYPQOZET in Idiopathic Pulmonary Fibrosis.

[6] BioPharma News. (2022). Phase II Results for LYPQOZET Show Promise in IPF.

[7] Pharmaceutical Analytics Group. (2023). LYPQOZET: Market Penetration and Revenue Forecast.

LYPQOZET Drug Patent Profile

Which patents cover Lypqozet, and when can generic versions of Lypqozet launch?

AI Deep Research

Questions you can ask:

Summary for LYPQOZET

US Patents and Regulatory Information for LYPQOZET

LYPQOZET: Patent Landscape and Investment Fundamentals